Sign up to receive our twice-weekly e-Newsletter
Experimental Treatments for HIV/AIDS
QUAD Pill
elvitegravir, boosting agent cobicistat, tenofovir, and emtricitabine
Booser
cobicistat
CCR5 Receptor Antagonists
PRO 140, PRO 542, PRO 2000
SCH 532706
TBR-652
Vicriviroc
Integrase Inhibitors
Elvitegravir (GS 9137)
S/GSK1265744
Maturation Inhibitors
BEVIRIMAT (MPC-4326, PA-456)
nNRTIs
TMC-278 (rilpivirine)
IDX899
NRTIs
Apricitabine (SPD754 / SPD756)
Elvucitabine (ACH-126,443, or Beta-L-Fd4C)
FDA-approved HIV
and AIDS Treatments
Protease Inhibitors
PIs
non Nucleoside Reverse
Transcriptase Inhibitors
nNRTIs
Nucleoside / Nucleotide
Reverse Transcriptase Inhibitors
NRTIs
Fixed-dose Combinations
Entry / Fusion Inhibitors
EIs
Integrase Inhibitors
Experimental Treatments
HIV and AIDS
Articles by Topic
Adverse Events
Opportunistic Infections
Metabolic Complications
Lipodystrophy - Fat Redistribution
Treatment Guidelines
Women/Children